1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Pediatric Cancer – Pipeline Review, H1 2013

Pediatric Cancer – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 56 pages

Pediatric Cancer – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Pediatric Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pediatric Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pediatric Cancer. Pediatric Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pediatric Cancer.
- A review of the Pediatric Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pediatric Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Pediatric Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pediatric Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Pediatric Cancer - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pediatric Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Pediatric Cancer 7
Pediatric Cancer Therapeutics under Development by Companies 9
Pediatric Cancer Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Pediatric Cancer Therapeutics - Products under Development by Companies 14
Pediatric Cancer Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Pediatric Cancer Therapeutics Development 16
Novartis AG 16
Hana Biosciences, Inc. 17
Innogene Kalbiotech Pte Ltd. 18
PharmaMar, S.A. 19
Polaris Group 20
Pediatric Cancer - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
panobinostat - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
vincristine sulfate - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Racotumomab - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
ADI-PEG 20 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
cyclophosphamide + vinorelbine tartrate - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
trabectedin - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
NTX-010 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Pediatric Cancer Therapeutics - Drug Profile Updates 42
Pediatric Cancer Therapeutics - Dormant Products 50
Pediatric Cancer - Product Development Milestones 51
Featured News and Press Releases 51
Jul 11, 2012: Scientists Develop New Strategy To Overcome Drug-Resistant Childhood Cancer 51
Feb 24, 2010: Enzon Opens Pediatric Study Of PEG-SN38 52
Jun 01, 2009: Cytokinetics Announces Non-Clinical Data Relating To GSK-923295 Presented At The 2009 Annual Meeting Of The American Society Of Clinical Oncology 52
Oct 23, 2008: Neotropix Announces Presentation Of Preclinical Results Of NTX-010 53
Jun 19, 2007: OSI Pharmaceuticals Begins Clinical Development Program of OSI-906 in Patients with Advanced Solid Tumors 53
Nov 02, 2006: Ziopharm Announces Preclinical Data Of ZIO-201 In Pediatric Cancers 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56



List of Tables

Number of Products Under Development for Pediatric Cancer, H1 2013 7
Products under Development for Pediatric Cancer - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Novartis AG, H1 2013 16
Hana Biosciences, Inc., H1 2013 17
Innogene Kalbiotech Pte Ltd., H1 2013 18
PharmaMar, S.A., H1 2013 19
Polaris Group, H1 2013 20
Assessment by Monotherapy Products, H1 2013 21
Assessment by Combination Products, H1 2013 22
Assessment by Stage and Route of Administration, H1 2013 24
Assessment by Stage and Molecule Type, H1 2013 26
Pediatric Cancer Therapeutics - Drug Profile Updates 42
Pediatric Cancer Therapeutics - Dormant Products 50



List of Figures

Number of Products under Development for Pediatric Cancer, H1 2013 7
Products under Development for Pediatric Cancer - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 21
Assessment by Combination Products, H1 2013 22
Assessment by Route of Administration, H1 2013 23
Assessment by Stage and Route of Administration, H1 2013 24
Assessment by Molecule Type, H1 2013 25
Assessment by Stage and Molecule Type, H1 2013 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.